Peptoid Compound Selective Binding to Breast Cancer Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breast cancer are ineffective in targeting cancer stem cells (CSCs), which are resistant to conventional therapies and contribute to tumor recurrence, due to the lack of specific markers and instability of antibody-based detection agents.
Innovation Solution
Development of a compound that selectively binds to CSCs, specifically to CD24−/CD44+ phenotype breast CSCs, which can be conjugated with detectable or therapeutic agents, such as gold nanorods for photothermal therapy, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-based detection agents are used to detect cancer stem cells, then detection capability is provided, but reliability deteriorates due to inherent instability of antibodies
Solution Approach 1:
The patent creates a synthetic small molecule copy that mimics the natural ligand (stat3 peptide) which binds to the cancer stem cell marker CD44. This synthetic compound (CL-1-19-1) replicates the binding function of natural ligands without the instability issues of antibody-based detection agents, providing both detection capability and reliability
Solution Approach 2:
The patent employs small molecule compounds instead of expensive, complex antibody structures. These small molecules are chemically stable, easier to synthesize, and can be modified with detectable agents, providing a more reliable and practical detection solution compared to unstable antibodies
2Measurement precision
If multiple antibodies are combined to detect CD24−/CD44+ phenotype cancer stem cells, then detection precision is improved, but device complexity increases
Solution Approach 1:
The synthetic compound CL-1-19-1 serves as a universal detector for CD44+ cancer stem cells. By designing a single small molecule that specifically binds to CD44 (the key marker for breast cancer stem cells), the patent eliminates the need for multiple antibodies required to detect the CD24−/CD44+ phenotype, thereby reducing complexity while maintaining detection precision
Solution Approach 2:
The patent extracts the essential binding function from complex antibody molecules and concentrates it into a single small molecule compound. By focusing on binding to the critical CD44 marker rather than requiring detection of multiple markers simultaneously, the solution simplifies the detection system while preserving the ability to identify cancer stem cells
Data Source
AI summary
The present disclosure provides a for peptoid compounds that bind selective to cancer stem cells (CSCs), particularly those associated with breast cancer. Conjugates of the peptoids to detactable labels and therapeutic agent are contemplated as are methods of diagnosing and treating breast cancer.